Faculty

Emanuele Angelucci
Italy
Bio
Emanuele Angelucci

Degree in Medicine: Bologna School of Medicine in 1984

General Hematology, Clinical Oncology and Internal Medicine Fellowship (Ancona University School of Medicine).

Director Hematology and Cellular Therapies and the Stem Cell Transplant Program and Cellular Therapies “Alberto Marmont” IRCCS San Martino Polyclinic Hospital in Genoa. 2016 – today

Over 400 scientific papers in indexed journals (Hindex 66 – Scopus May 2024) particularly in the field of treatment of hematologic malignancies and in hematopoietic cell transplantation and problems related to iron overload and toxicity (N Engl J Med 2000, Blood 2002, Ann Intern Med 2020).

In the field of transplantation in hemoglobinopathies he is co-author of the main studies published since the preliminary experiences (N Engl J Med 1987, 1990, 1993 and 2000, Lancet 1985, 1992 and 1993, Ann Inter Med 2002, Blood 1997, 1997, 2002) as well as main author of the European guidelines for transplantation in hemoglobinopathies: Haematologica 2014.

Chair of the Hemoglobinopathies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Mutlu Arat
Turkey
Bio
Mutlu Arat, MD graduated from Hacettepe University Medical School in 1991. In Ankara University Faculty of Medicine he attended internal medicine program. In 1997-1998 as scholar of Austrian Government worked in Vienna for stem cell transplantation and cytogenetics. In 2001 he finished the Hematology subspecialty program in Ankara University. After 2000 his main clinical research area based mainly on hematological malignancies treatable with HSCT. He worked at EHA Educational Committee and as secretary of LEWP in EBMT. He is active JACIE inspector since 2004, and member of Advisory Scientific Council at the Turkish Ministry of Health. He was the founding director of the Şişli-Istanbul Florence Nightingale Hospital HKHT Center between 2010-2024. In the past ten years the center accomplished 1000 transplants, an done of the pioneering alternative donor HSCT centers in Turkey. Main clinical research area is late effects after HSCT, GVHD, leukemia, lymphoma and myeloma, management of relapse & refractory patients, use of artificial intelligence in Hematology & HSCT field.
Daniele Avenoso
Italy
Andrea Bacigalupo
Italy
Bio
Andrea Bacigalupo is currently Consultant at the Hematology Department and Transplant Unit at Policlinico Gemelli , Catholic University, in Rome , Italy. He was Head of the Transplant Unit in Genova San Martino (1989-2014) and then Head of the Transplant Unit at Gemelli in Rome (2015-2019). He has been involved in stem cell transplants since 1976, and in the European Group for Blood and Marrow Transplants (EBMT) since 1977. He has conducted several prospective clinical trials in patients with aplastic anemia and in patients undergoing allogeneic transplants: in particular in the field of GvHD. His main interests are bone marrow failure, GvHD and related complications, and graft versus leukemia reactions. He is a member of several national and international hematology societies. He is Associate Editor of the journal Transplant and Cellular Therapy. Prof Bacigalupo has published over 600 articles in peer-reviewed journals. His H-Index is 100.
Michael Bishop
USA
Bio
Dr. Michael Bishop is Professor of Medicine and the Director of the David and Etta Jonas Center for Cellular Therapy at the University of Chicago. Dr. Bishop’s research focuses on the development and conduct novel clinical trials in hematopoietic stem cell transplantation and cellular therapy. Particular areas of interest include the therapeutic use of T cells to treat advanced hematologic malignancies. In addition, his research program is focused on methods to prevent and treat recurrent disease following hematopoietic stem cell transplantation, with a primary focus on B-cell malignancies.
Francesca Bonifazi
Italy
Bio
Francesca Bonifazi is the Director of the Adult Transplant Program in Bologna, and the head of Advanced Cellular Therapies Unit in Bologna, Italy. She has been the President of the Italian Society of HSCT (GITMO) (2015-19). The major scientific fields of interest are GVHD prophylaxis, transplantation from alternative donors, transplantation in the elderly, transplantation in acute leukemia, early complications.
Jaime Sanz Caballer
Spain
Yi-Bin Chen
USA
Bio
Yi-Bin Chen, MD is the Director of the Hematopoietic Cell Transplant and Cell Therapy Program at Mass General Brigham Cancer Institute. He is the inaugural Allan Rogers, Jr. and Cara J. Rogers Endowed Chair and a Professor of Medicine at Harvard Medical School. Dr. Chen has spent his career in clinical investigation with the goal of improving outcomes for patient undergoing hematopoietic cell transplantation. He has led early pilot and phase I efforts through pivotal international phase 3 trials in almost all aspects of transplantation. He has collaborated extensively through his work with industry collaborators, in the MAGIC consortium, the BMT CTN, ASTCT and EBMT. Most recently, he has focused his efforts on novel agents for the prevention and treatment of graft-vs-host disease (GVHD) as well as the incorporation of maintenance therapies after transplantation to prevent disease relapse.
Yael Cohen
Israel
Bio
Yael Cohen, MD (Tel Aviv, Israel)

Director of Myeloma Unit, Tel Aviv Sourasky Medical Center, Hematology Department, Tel Aviv, Israel

Prof. Yael Cohen graduated from the faculty of medicine at the Tel Aviv University. She completed with distinction her specialization in Internal Medicine at the Sheba Medical center, Israel, and completed her fellowship in hematology at the Rabin Medical Center, Israel.

Prof. Cohen heads the Myeloma Unit at the Tel Aviv Sourasky Medical Center. She is a professor of medicine at the Tel Aviv University faculty of medicine. She leads and participates in multiple research projects and clinical trials in Israel and internationally. Research interest include clinical and translational research in myeloma. Prof Cohen has over 100 publications in international medical meetings and peer reviewed journals.

Prof. Cohen serves as the chair of the Israeli Myeloma working group within the Israeli society of Hematology, and is a member of the Israeli national central ethics committee for clinical trials.
Charles Craddock
UK
Bio
Professor Charles Craddock is Professor of Haemato-oncology at the University of Warwick and Academic Director of the Centre for Clinical Haematology at University Hospitals Birmingham. Professor Craddock is Chair of the UK Stem Cell Strategic Oversight Committee and was Medical Director of Anthony Nolan from 2010–2014. He is a past President of the British Society of Haematology. Professor Craddock pioneered the development of both the UK Haemato-oncology Trials Acceleration Programme and stem cell transplant trials network, IMPACT. In 2021 he founded Accelerating Clinical Trials Ltd, an innovative haemato-oncology trials delivery vehicle. He has published more than 275 papers in peer reviewed journals. Professor Craddock was awarded the CBE for services to medicine in the 2016 New Year’s Honours list and elected a Fellow of the Academy of Medical Sciences in 2020.
Marcos de Lima
USA
Bio
Nihar Desai
Canada
Fernando Barroso Duarte
Brazil
Bio
Dr. Fernando Barroso Duarte, Medical Specialist in Hematology and Hemotherapy (ABHH), PhD in Surgery from the Federal University of Ceará, and postdoctoral fellow at the Fred Hutchinson Cancer Research Center (Fred Hutch)/Seattle Cancer Care Alliance (USA).

He is an Adjunct Professor in the Department of Surgery at UFC, a physician at the University Hospital Walter Cantídio/EBSERH/UFC, and Chief of the Hematology, Clinical Oncology, and Bone Marrow Transplant Service.

He is currently the President of the Brazilian Society of Bone Marrow Transplantation (SBTMO) and coordinator of the Latin American Bone Marrow Transplant Registry in Myelodysplasia since 2016. Additionally, he is the Editor-in-Chief of the Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT).
Carlo Dufour
Italy
Bio
Carlo Dufour chairs the Hematology-Oncology Department and the Hematology Unit in G. Gaslini Research Children’s Hospital, Genova, Italy. He founded the Marrow Failure Syndromes Study Group within the Italian Pediatric Hemato-Oncology Association (AIEOP). Acted as Chairman of the Working Party of the Severe Aplastic Anemia (WPSAA) and as Board member of the European Society for Blood and Marrow Transplantation (EBMT) and as member of the Scientific Committee on Marrow Failures of the American Society of Hematology. He currently serves as the chairman of the Scientific Working Group on Granulocyte and Constitutional Marrow Failure Disorders of the European Hematology Association (EHA) and as a member of the Guidelines Commettee of European Hematology Association (EHA).

In august 2020 has been awarded by the EBMT along with Prof Regis Peffault de Latour and prof Antonio Risitano, with the Van Bekkum award as Co PI of the prospective randomized trial RACE (Comparison of classical IST ± Eltombopag) in Severe Aplastic Anemia.
Robin Foà
Italy
Bio
Prof. Robin Foà is Head of Hematology, Sapienza University of Rome up to November 2019. Currently, Professor Emeritus of Hematology, Sapienza University of Rome. He earned his medical degree in Turin, Italy, and specialized in pediatrics and in hematology. Worked at the MRC Leukaemia Unit, Hammersmith Hospital, London between 1976 and 1979. Sabbatical at Memorial Sloan-Kettering Cancer Center, New York, between 1991 and 1992.
He is part of the European Leukemia Network and referee for national and international funding agencies. Chairman of the Scientific Committee of the 4th EHA Congress, Barcelona 1999, councilor of EHA until December 2002, and member of the Education Committee of EHA until December 2005. President-Elect, President and Past-President of EHA during the years 2007-2013. Chairman Education Committee and Outreach Unit of EHA up to June 2017. Member of EHA’s Global Outreach Committee. Has been chairman of the GIMEMA Working Party for chronic lymphoproliferative disorders, and member of the board of the Working Party for acute leukemias (and responsible of the ALL protocols).
Has authored over 850 papers and reviews, as well as a number of books. Has been co-editor of Leukemia and Lymphoma, and associate editor of the British Journal of Hematology and of The Hematology Journal. Editor-in-chief of The Hematology Journal up to December 2004 and of Haematologica from January 2005 to February 2008.
At the 23nd EHA Congress in Stockholm (2018) he has been awarded the EHA Education & Mentoring Award and at the EHA 26th Congress in Frankfurt (2023) he received the EHA José Carreras Award.
Nico Gagelmann
Germany
Bio
Resident physician University Medical Center Hamburg-Eppendorf under supervision of Prof. Nicolaus Kröger in the Department of Stem Cell Transplantation

Medical school in Hamburg from 2014-2020

Co-Chair EBMT Trainee Committee

Chair EBMT-CMWP subcommittee on CAR-T for plasma cell disorders

Published work on: myelofibrosis, myeloma, MDS, conditioning, relapse prevention
Eleni Gavriilaki
Greece
Hildegard Greinix
Austria
Bio
Prof. Hildegard T. Greinix

Medical University of Graz, Austria

I have a long-standing research interest in allogeneic hematopoietic cell transplantation (HCT) including transplant immunology with acute and chronic graft-versus-host disease (GVHD) and induction of transplant tolerance. I am a participant in the NIH Consensus Development Project on chronic GVHD focusing on innovative treatments. My translational research projects have been focused on immune-based soluble and cellular biomarkers predictive and diagnostic for chronic GVHD. Another main preclinical and clinical research interest consists of the exploitation of immunotherapeutic strategies in hematologic malignancies including post-transplant cellular therapies. I am the Head of the Division of Hematology of the Medical University of Graz, Austria and I am the chair of the Austrian Stem Cell Transplant Group.
Carmelo Gurnari
Italy
Bio
After graduating from Pavia medical school (2015) with a thesis in Pediatric Hematology/Oncology, Dr. Gurnari completed his training in Hematology at the University of Rome, Tor Vergata and then decided to continue his education with a Ph.D program in “Immunology, Molecular Medicine and Applied Biotechnology”. Simultaneously, Dr. Gurnari has been working since 2019 at the Department of Translational Hematology and Oncology Research of Cleveland Clinic (USA) focusing on the genomics of bone marrow failure disorders and myeloid neoplasia. His clinical and translational research expertise encompasses myeloid malignancies with a special focus on germline predisposition and MDS. Dr. Gurnari is a member of the EHA, ASH, and of the EBMT, for which he serves as vice-chair of the CMWP MDS subcommittee. In these years, Dr. Gurnari has been awarded several international prizes such as the Tito Bastianello Young Investigator Award in MDS research and the ASH-IPIG Award for PNH research.
Shernan Holtan
USA
Christopher Hourigan
USA
Xiaojun Huang
China
Bio
Prof. Xiaojun Huang, MD

Professor of medicine;

Member of Chinese Academy of Engineering;

Chairman of Peking University Institute of Hematology, PUPH

Director of National Clinical Research Center for Hematologic Diseases, P.R.China

Fellow of the Chinese Academy of Medical Sciences

Foreign Corresponding Member of the French Academy of Medicine

Other Experience and Professional Memberships

Winner of Center for International Blood and Marrow Transplant Research (CIBMTR) Distinguished Service Award

Winner of International Academy for Clinical Hematology (IACH) International Collaboration Award

Chairman, Chinese Association of Hematologists, (CMDA)

Director, China Marrow Donor Program

Executive editor,Journal of Translational Internal Medicine

Associate Editor, British Journal of Hematology

Associate Editor, Journal of Hematology and Oncology
Gloria Iacoboni
Spain
Nicolaus Kröger
Germany
Bio
Dr. Nicolaus Kröger is Professor of Medicine and Medical Director of the Department of Stem Cell Transplantation at the University Medical Center Hamburg-Eppendorf, Germany. Prof. Kröger is board certified in Hematology-Oncology and Internal Medicine.
He served also as chairman of the German Stem Cell Working Group (DAG-KBT) from 2014-2020 and is member of several editorial boards such as Blood, Haematologica, Bone Marrow Transplantation and Biology ofBlood and Marrow Transplantation. He is also member of numerous Scientific Committees such as ASH, EHA, and ESH.
He has received several awards for his work to date including the prestigious EBMT van Bekkum Award in 2015. In 2020 he was awarded as Doctor Honoris Causa from the University Belgrade.
Prof. Kröger has published extensively in his area of expertise and has contributed to more than 650 publications in peer-reviewed journals such as NEJM, Lancet, JCO, JNCI, PNAS, Blood and Leukemia.
Franco Locatelli
Italy
Bio
Franco Locatelli is a Full Professor of Pediatrics at the Catholic University of the Sacred Heart in Rome and Head of the Department of Paediatric Haematology and Oncology and Cell and Gene Therapy, at the Bambino Gesù Children’s Hospital in Rome. He has been the President of the Italian Association for Pediatric Haematology-Oncology AIEOP from 2004 to 2006, and served as chairman of the European EWOG-MDS consortium from 2005 to 2011. Professor Locatelli is an expert of hematological malignant and non-malignant disorders of childhood. Prof. Locatelli is the author or co-author of 1.349 peer-reviewed articles published in international journals (including New England Journal of Medicine, JAMA, Nature, Nature Genetics, Nature Communications, The Lancet, etc.) with more than 62.570 citations and he has an H-index of 120 (Scopus source). Since February 2019 until now, Prof. Locatelli is serving as President of the National Council of Health (Consiglio Superiore di Sanità). On December 2021, he was nominated 1st Class/Knight Grand Cross (Cavaliere di Gran Croce) by the President of the Italian Republic.
Peihua Lu
China
Bio
Medical Executive President of Lu Daopei Hospital and Lu Daopei Institute of Hematology. Dr. Lu graduated from Peking University Medical School, and had her residency training at the University of Nebraska Medical Center in USA. She completed her hematology and oncology fellowship at Stanford University Medical Center.

American Board Certified Hematologist & Oncologist, with American and Chinese Medical License

Member of the Fourth Executive Committee of the Department of Oncology, Capital Medical University

Chairman of Hematology Specialty Committee of Chinese Non-government Medical Institutions Association (CNMIA)

Member of Chinese Marrow Donor Program (CMDP) Expert Committee

Member of Chinese Society of Clinical Oncology (CSCO) Anti-Leukemia Alliance Expert Committee

Member of the Hematology Translational Medicine Committee of China Anti-Cancer Association (CACA)

Member of the Seventh Council of Beijing Medical Education Association
Maximilian Merz
Germany
Bio
Professor Dr. med. Maximilian Merz
University of Leipzig
Department for Hematology, Cellular Therapy and Hemostaseology
Leipzig, Germany

Prof. Merz is Professor of Medicine (Außerplanmäßiger Professor) at the Medical Faculty at University of Leipzig, Leipzig, Germany where is an attending physician and clinician scientist. Since 2022 he is the Head of Early Clinical Trials Unit Leipzig (ECTUL). Last year he received the Translational Research Award by the International Myeloma Society and in 2022 the Helga-Reifert Award from Helga-Reifert-Stiftung for experimental cancer research.
Ivan Moiseev
Russia
Bio
Ivan Moiseev graduated Pavlov Medical University in Saint-Petersburg in 2007, completed his hematology training in 2010 and started to work in RM Gorbacheva Research institute at Pavlov University. In 2013 he defended his PhD thesis on veno-occlusive disease and thrombotic microangiopathy after allogeneic stem cell transplantation. Since 2013 his scientific interests focus on graft-versus-host disease and other complications of stem cell transplantation. Since 2017 he is the head of research at RM Gorbacheva Research institute and since 2021 holds the position of professor at Pavlov University. He is an active member of the EBMT and the early complications sub-committee chair of the Transplant Complications Working Party.
Lori Muffly
USA
Bio
Arnon Nagler
Israel
Bio
Professor Arnon Nagler, MD, MSc
Chaim Sheba Medical Center, Israel

– Director of the Division of Hematology, Chaim Sheba Medical Center, Israel
– Director of Bone Marrow transplantation and Cord Blood Bank, Chaim Sheba Medical Center, Israel
– Professor of Medicine at the Tel Aviv University, Tel Aviv, Israel
– One of the pioneers of the non-myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders (Blood 1998)
– Established the first public cord blood bank and performed the first cord blood transplanataion in Israel
– Leader of the Alternative donor subcommittee of the ALWP of the EBMT from 2008-2010
– Leader of the RIC subcommittee of the ALWP of the EBMT – since 2010
– Serves on the Editorial Board of several BMT and Hematology Journals and is a Section Editor for Leukemia
– Chair of the Acute Leukemia Working Party (ALWP) of the EBMT

Dr Nagler received his medical training at the Hebrew University-Hadassah Medical School, Jerusalem, Israel; he then carried out a Postdoctoral research fellowship in hematology and bone marrow transplantation at “Stanford University Hospital” Palo Alto, CA, in the USA, from 1986 to 1990.
Dr Nagler serves on the Board of Directors of Netcord organization of cord blood banks and was the Netcord Threasurer from 2010-2013.
Dr Nagler has received several awards including the best scientific abstract award of the ASBMT/CIBMR Tandem meeting (2004) and the best clinical abstract award of the NMDP Council Meeting (2004). In addition, Dr Nagler is a popular speaker and has made numerous, invited, international presentations and many Oral presentations on almost annual basis in all international transplantation and hematology meetings – ASH,ASBMT/CIBMTR, EBMT, EHA, Exp Hematology (including a presentation at the presidential symposium) and invited presentation at the Gordon conference (Boston USA).
Olaf Penack
Germany
Bio
Prof. Olaf Penack (M) obtained his M.D. from the University in Göttingen in 1999 and joined Charité as a clinical fellow and scientist in 2002. In 2009, he completed a post-doctoral fellowship at the Memorial Sloan Kettering Cancer Center in New York City. Currently, he is Director of the Advanced Cellular Therapy Program in the department of Hematology, Oncology and Tumorimmunology at the Charité Universitätsmedizin Berlin, Campus Virchow Clinic. His aim is to improve outcome of cellular therapies by optimized clinical management as well as by development of novel therapeutic approaches. One specific focus of Olaf Penack’s work is to study the function of the endothelium during cellular therapies in pre-clinical models as well as in clinical studies. This knowledge can facilitate development of endothelium-based therapeutic approaches in the fields of stem cell transplantation as well as cellular therapies.
Zinaida Perić
Croatia
Bio
Zinaida Peric is a hematologist at the University Hospital Centre Rijeka and Associate Professor at the School of Medicine, University of Rijeka, Croatia. Dr Peric’s research activity is focused on graft-vs-host disease and the role of gut microbiota in hematology and stem cell transplantation. Her clinical interests focus on acute leukemias and complications of transplantation and cellular therapies. Dr Peric is the Head of Hematology Department the University Hospital Centre Rijeka, a Croatian referral centre for supportive care and quality of life. She was also a Chair of the Transplant Complications Working Party and now GVHD subcommittee and Co-leader of ALL subcommittee (Acute Leukemia Working Party) of the European Group for Blood and Marrow Transplantation (EBMT).
Alexander Perl
USA
Alessandro Rambaldi
Italy
Bio
Alessandro Rambaldi, MD, is Full Professor of Hematology of the Department of Oncology and Hematology at the University of Milan, Italy. Following his medical degree, he was Associate in Pathology at the Dana Farber Cancer Institute, Boston, USA. Since 2006 he is the Director of the Hematology and Bone Marrow Transplant Unit at the Ospedale Papa Giovanni XXIII, Bergamo, Italy. He is member of the American Society of Hematology (ASH), European Hematology Association (EHA), European Blood and Marrow Transplant group (BMT). From 2010 he served JACIE as Vice Chair and Chair from 2010 to 2015. From 2011 to 2014 he was President of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

His scientific interest ranges from translational research to academic clinical trials in which he pioneered the integration of molecular evaluation of minimal residual disease in the treatment strategy of adult patients with acute lymphoblastic leukemia and non-Hodgkin’s lymphomas. He also led several trials in the field of acute leukemia, lymphomas chronic myeloproliferative neoplasms and allogeneic stem cell transplantation. A current special research interest is the development of innovative cellular therapies for the treatment of leukemia relapse after allogeneic stem cell transplantation.

Prof. Alessandro Rambaldi has published more than 600 manuscripts in peer-reviewed journals such as Journal of Clinical Oncology, Lancet Oncology, Lancet Haematology, Blood, Leukemia, Haematologica and many others for which he routinely serves as referee.
Antonio Risitano
Italy
Bio
Antonio M. Risitano, MD, PhD
AORN San Giuseppe Moscati, Avellino, Italy

Antonio Risitano is Head of the Hematology and BMT Unit at the AORN San Giuseppe Moscati in Avellino, Italy. He graduated in 1997 from the University of Napoli Federico II Medical School in Naples, Italy, where he also completed a residency in haematology under the mentorship of Professor Bruno Rotoli. In 2000, he was awarded a fellowship at the haematology branch of the National Institutes of Health, where he dedicated his time to experimental work on the pathophysiology of bone marrow failure syndromes, under the guidance of Doctor Neal Young. He then moved back to Naples to complete his PhD, serving as a clinical attendant and subsequent research associate in the haematology unit. Professor Risitano was Director of the Bone Marrow Transplantation Program at the University of Napoli Federico II until July 2020, when he moved to his current role.

Professor Risitano has previously focused his activity on clinical management and basic science in the field of aplastic anaemia, paroxysmal nocturnal haemoglobinuria, and idiopathic acquired cytopenias, as well as stem cell transplantation. He has actively contributed to the progress made in this field, with a number of scientific publications describing both clinical trials and biological insights. His current activity includes the management of patients receiving bone marrow transplantations, as well as of those with any bone marrow failures syndrome, including paroxysmal nocturnal haemoglobinuria. He also runs a number of research activities, both clinical and experimental, in the field of paroxysmal nocturnal haemoglobinuria, aplastic anaemia, and bone marrow transplantation, as well in other malignant and non-malignant haematological diseases. Professor Risitano has authored more than 100 publications in the top haematology journals.
Marie Thérèse Rubio
France
Bio
Pr Marie Thérèse Rubio

MD, PhD

Affiliations: Hematology department, Nancy university Hospital, France

Pr Marie Therese Rubio is the head of allogeneic BMT and cell therapy unit of Nancy University Hospital in France and of a research group in the University of Lorraine in Nancy. Her work is dedicated to the optimization of GVHD prophylaxis in BMT patients, on immune reconstitution and modulation after allogeneic HSCT by invariant NKT cells.
Thomas Schroeder
Germany
Bio
Bart Lee Scott
USA
Bio
Bart Scott is a medical oncologist at Fred Hutchinson Cancer Research Center in Seattle, Washington. He is Professor of Medicine in the Division of Oncology at the University of Washington Medical Center. . Dr. Scott received his medical degree from the University of South Alabama. He then completed his internship and residency at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He completed his fellowship in medical oncology at the University of Washington in Seattle. Dr. Scott has participated in a number of clinical trials involving myelodysplastic syndromes and myeloproliferative neoplasms. He has published numerous articles in journals such as American Journal of Medicine , Leukemia & Lymphoma , Blood , and Journal of Clinical Oncology . He was a co-author on the first edition of the NCCNN guidelines for MPN. He has served as an Associated Editor for Biology of Blood and Marrow Transplantation and is currently an Associate Editor for Leukemia. He is a member of the American Medical Association, the American Society of Hematology, the American Society of Clinical Oncology, and the Southwest Oncology Group, among many others.
Bronwen Shaw
USA
Bio
Dr. Bronwen Shaw is the Chief Scientific Director of the Center for International Blood and Marrow Transplant Research (CIBMTR) at the Medical College of Wisconsin, where she is a BMT physician. Much of her research has been dedicated towards improving donor selection algorithms by understanding the impact of HLA matching and other donor factors on transplant outcomes, including disease relapse.
Avichai Shimoni
Israel
Bio
Avichai Shimoni, MD. Medical specialist in internal medicine and Hematology. Completed medical education in Hadassah Medical School in Jerusalem in 1988. Had clinical fellowship in bone marrow transplantation in MD Anderson Cancer Center, Houston, Texas, between the years 1998-2000. Currently, the director of the department of Bone Marrow Transplantation and co-director of the Division of Hematology at the Chaim Sheba Medical Center, Tel-Hashomer. Professor of Hematology in Tel-Aviv University.
Robert Soiffer
USA
Bio
Robert J. Soiffer, MD, is Chief of the Division of Hematologic Malignancies, Chair of the Executive Committee for Clinical Programs, Vice Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, and Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology, Harvard Medical School.

Dr. Soiffer conducts research focused on modulation of immune responses in the setting of hematopoietic stem cell transplantation. The ultimate goal for his clinical trials and research grants is to optimize graft versus leukemia activity without inducing graft versus host disease.

Dr. Soiffer is a former President of the American Society for Blood and Marrow Transplantation and Past-Chair of the Advisory Board for the Center for International Blood and Marrow Transplant Research. He serves on the Executive Steering Committees for Blood and Marrow Transplant Clinical Trials Network. Dr. Soiffer is a member of the Board of Directors for the National Marrow Donor Program and served as Chair of the Board from 2020 until 2022. Dr. Soiffer serves on the National Cancer Institute’s Leukemia Steering Committee

Dr. Soiffer has co-authored more than 400 peer-reviewed manuscripts and numerous book chapters, review articles, editorials, and monographs. Dr. Soiffer has received several honors and awards including the Casty Family Achievement in Mentoring Award from Dana-Farber, the Brian O’Dell Memorial Research Award from the Leukemia and Lymphoma Society, the George Thorn Award for Outstanding Teaching at Brigham and Women’s Hospital, and the Claire W. and Richard P. morse Research Award.
Pieter Sonneveld
Netherlands
Bio
Pieter Sonneveld received his medical degree from the Erasmus University in Rotterdam, The Netherlands in 1977. In 1980 he completed a Ph.D. thesis on the pharmacology of Adriamycin at the University of Leiden (DW van Bekkum & HM Pinedo, promotores). He received a Fogarty Fellowship and worked at the National Cancer Institute, Bethesda, USA.

Dr. Sonneveld is Professor of Hematology at the Erasmus MC and Erasmus University Rotterdam and Chair of the Erasmus MC Cancer Institute in Rotterdam. From 2011 to 2017 he has been the head of the department of Hematology. His research focus is on clinical and translational aspects of multiple myeloma. His myeloma research group in Erasmus MC has been very active in molecular diagnostics and micro-environment of myeloma.

He is vice-chairman of the HOVON Myeloma Working Group and coordinates HOVON and EMN clinical trials. Dr. Sonneveld is one of the founders of the European Myeloma Network and has been chairman since. Within EMN, he coordinates a cooperative network for independent clinical trials in Europe. EMN currently runs international trials and registration trials for novel treatments in myeloma.

He has been Treasurer and President (2017-2019) of the European Hematology Association EHA, and chair of its Scientific Working Group Committee. He has chaired the Scientific Program Committee of the 19th EHA congress in Milan 2014 and of the EMN Myeloma meetings in 2018 and 2021.

He serves on the Scientific Advisory Boards of the International Myeloma Society, the International Myeloma Foundation and the Multiple Myeloma Research Foundation and is a member of the International Myeloma Working Group. Dr Sonneveld has been a member of many Editorial Boards and has authored more than 600 peer reviewed scientific publications and book chapters. He has received numerous grants for his research.

In 2015 he was awarded the international Robert Kyle Award in Multiple Myeloma. In 2019 he received the Hubertus Wald Award for Cancer Research from Germany and in 2022 he received the International Waldenstrom Lifetime Achievement Award by the International Myeloma Society.
Rainer Storb
USA
Bio
Dr. Rainer Storb is a Member of the Fred Hutchinson Cancer Research Center and a Professor of Medicine at the University of Washington in Seattle, WA. After joining the 2-person laboratory of Dr. E. Donnall Thomas in 1965, he has been one of a handful of individuals instrumental in moving allogeneic hematopoietic cell transplantation (HCT) from what was then thought to be a method plagued by insurmountable complications to what’s now considered standard therapy of patients with malignant and nonmalignant blood disorders. This has included developing HCT approaches that could be expanded to include patients who are too old or medically infirm to tolerate more conventional transplant approaches. A long-term colleague and collaborator, Dr. Brenda Sandmaier, and he now focus on developing potent and far less toxic conditioning regimens for allogeneic HCT, using monoclonal antibody-guided radioimmunotherapy with a very short-lived, highly potent, alpha-emitting radionuclide, astatine-211, that has a pathlength of only 60 micron and thus few, if any, off-target effects.
Jan Styczynski
Poland
Bio
Prof. Jan Styczynski, MD is the Head of the Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. National Consultant in Pediatric hematology and oncology in Poland. Former Chairman and current Secretary of Infectious Diseases Working Party (IDWP) of European Society for Blood and Marrow Transplantation (EBMT). Vice-President of ECIL (European Conference on Infections in Leukemia). Chairman of Infectious Diseases Working Group in Polish Society of Pediatric Hematology and Oncology. Donor of hematopoietic stem cells.
Marion Subklewe
Germany
Bio
Marion Subklewe is Professor of Internal Medicine with focus on Cellular Immunotherapy within the medical department for hematology / oncology at the LMU – University Hospital Munich. She is Head of the immunotherapy program in hematology and the CAR T program at the University Hospital Munich, leading an intermediate care unit and an early clinical trial unit as well as a large outpatient clinic for pts with acute leukemias and aggressive lymphomas. She is heading the lab for Translational Cancer Immunotherapy at the Gene Center Munich with focus on translational research in t cell based immunotherapy. Her research is focused on understanding mode of action and mode of resistance of bispecific and bifunctional antibody constructs. Current research integrates an adapter CAR T cell platform and combinatorial approaches in the setting of AML. She is speaker of the national “Harmonize MRD Flow” consortium and member of the ELN working group on MRD. She is Principal Investigator in I-IT trials in AML and ALL as well as in > 30 oligo – and multicentric C-IT trials in leukemias and lymphoma.
Felicitas Thol
Germany
Magnus Tobiasson
Sweden
Sumithira Vasu
USA
Zhang Xi
China